Inflammatory Bowel Diseases (IBD)
12
4
6
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 12 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (12)
Integrated Clinical-Occupational Management for Workers With Chronic Noncommunicable Diseases
IBD Biomarker Discovery and Validation Platform
Epidemiological Evaluation Of Chronic Kidney Disease In Pediatric Patients With Inflammatory Bowel Disease
VIBRANT-IBD: Brain Effects of Non-Invasive Vagus Nerve Stimulation in IBD Remission
NORDTREAT Prospective Study on Inflammatory Bowel Disease
BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)
Study of Tissue Repair in Inflammatory Bowel Disease Exploiting Organoid Technology
Evaluating the Effectiveness of 68Ga-grazytracer PET/CT in Inflammatory Bowel Disease
Development and Validation of a New Paediatric Inflammatory Bowel Disease NUTrition Risk Score (PIBD-NUTS)
The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing Spondylitis
Osteopathic Approach in Inflammatory Bowel Diseases
Fecal Microbiota Transplantation in Pediatric Patients